Recursion Pharmaceuticals Inc. (RXRX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.83 (-4.96% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RXRX ranks #454 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RXRX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 5.0%, and ROIC of -35.0%. By comparison, ADMA (ADMA Biologics Inc) holds a C+ grade (69/100 RQD, P/E 17.9x, ROIC 32.9%, cap $2.48B) and BCRX (BioCryst Pharmaceuticals Inc.) posts a C+ grade (67/100 RQD, P/E 8.3x, ROIC 85.0%, cap $2.11B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).
Per RXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601830), Recursion Pharmaceuticals Inc. generated $74.7M in revenue (+26.9% YoY), -$644.8M in net income, and -$378.3M in free cash flow against $1.47B in total assets and $154.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 1.59 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While RXRX currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.80) and Max Pain ($4.02) forces dealer call-delta covering toward $5.50.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Recursion Pharmaceuticals Inc. (RXRX) dropped -4.96% to $3.83, trading at 43% of its 52-week range ($2.77 – $5.24). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Recursion Pharmaceuticals has had a rough longer term share price record, yet fresh clinical updates are keeping attention on what the market is willing to pay for its sales today. With the stock back in focus ahead of n
These two companies could move in different directions over the medium term.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +26.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RXRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RXRX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Recursion Pharmaceuticals Inc. (RXRX) ranks #454 by composite RQD confidence (40/100, grade D-) and #231 by equity capitalization ($2.29B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ADMA currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with RXRX at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RXRX
ACTIVE
Recursion Pharmaceuticals Inc. | D- | 40/100 | — | 5.0% | -35.0% | -4.96% | $2.29B | Benchmark Subject |
| ADMA ADMA Biologics Inc | C+ | 69/100 | 17.9x | 57.4% | 32.9% | -3.07% | $2.48B | /adma-vs-rxrx → |
| BCRX BioCryst Pharmaceuticals Inc. | C+ | 67/100 | 8.3x | — | 85.0% | -2.66% | $2.11B | /bcrx-vs-rxrx → |
| VCEL Vericel Corporation | D+ | 58/100 | 133.0x | 74.4% | 3.4% | +0.62% | $2.07B | /vcel-vs-rxrx → |
| BEAM Beam Therapeutics Inc. | E | 33/100 | — | — | -32.1% | -4.99% | $2.67B | /beam-vs-rxrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Recursion Pharmaceuticals Inc. (RXRX) reported GAAP revenue of $74.7M (+26.9% vs. FY2024 revenue of $58.8M , and +67.5% cumulative change since FY2023) , GAAP net income of -$644.8M, operating cash flow of -$371.8M, and free cash flow of -$378.3M (-1.5% YoY). On the balance sheet, RXRX closed FY2025 with $1.47B in total assets against $154.5M in total debt (Altman Z-Score: 1.59, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $74.7M | -$644.8M | -$371.8M | -$378.3M | $1.47B | $154.5M |
| FY2024 (FY) | 2024-12-31 | $58.8M | -$463.7M | -$359.2M | -$372.9M | $1.45B | $186.2M |
| FY2023 (FY) | 2023-12-31 | $44.6M | -$328.1M | -$287.8M | -$289.8M | $1.39B | $325.7M |
As of 2026-11-03, Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.83 (-4.96% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RXRX ranks #454 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RXRX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 5.0%, and ROIC of -35.0%. By comparison, ADMA (ADMA Biologics Inc) holds a C+ grade (69/100 RQD, P/E 17.9x, ROIC 32.9%, cap $2.48B) and BCRX (BioCryst Pharmaceuticals Inc.) posts a C+ grade (67/100 RQD, P/E 8.3x, ROIC 85.0%, cap $2.11B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).
Per RXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601830), Recursion Pharmaceuticals Inc. generated $74.7M in revenue (+26.9% YoY), -$644.8M in net income, and -$378.3M in free cash flow against $1.47B in total assets and $154.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
RXRX last traded at $3.83 (-4.96% on volume of 22,571,076 shares), positioning the stock +0.79% above its 50-day simple moving average ($3.80) and +8.81% above its 200-day simple moving average ($3.52). Across its 52-week range of $2.77 to $5.24, RXRX sits at the 42.9% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.35 to $4.31).
Recursion Pharmaceuticals Inc. (RXRX) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.83 (-4.96% 1D, market capitalization $2.29B).
Recursion Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. It is a biotechnology company with a market capitalization of $2.5B. Reported revenue was $74.7M in FY 2025, indicating a revenue base still small relative to operating losses.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Recursion Pharmaceuticals Inc. (RXRX) reported $74.7M in annual revenue (up from $58.8M in FY2024, +26.9% YoY) and -$644.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($44.6M revenue, -$328.1M net income) through FY2025, RXRX scaled operating cash flow to -$371.8M and free cash flow to -$378.3M, backed by $1.47B in total assets against $154.5M in total debt.
Investors should watch whether future partnership milestones materially change the revenue trajectory, since the current revenue base is small against operating losses.
Real-time company headlines, analyst actions, and sector developments for Recursion Pharmaceuticals Inc. (RXRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Recursion Pharmaceuticals Inc. (RXRX) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in RXRX in my $100K Virtual Cash book at $4.03. Reported cash of $743.3M against $154.5M in debt provides a meaningful liquidity cushion while institutional whale-flow scores 16 / 20.. Trading inside a $2.77–$5.32 52-week range with -14.95% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.
@BearTrap_Alert Shorting a 13/20 institutional whale-flow stock at $4.03 is dangerous when funds are rotating into Health Care.
Careful chasing RXRX at $4.03. ROIC of -35%, FCF yield of -14.95%, and an Altman Z-Score of 1.59 signal a cash-burning balance sheet under stress.. Gross margin is 5.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.39 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: